- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Cinthya Pena Orbea Discusses Socioeconomic Impacts on Sleep-Disordered Breathing
Many socioeconomic factors, such as neighborhood factors, access to care, and education can influence sleep, explained Cinthya Pena Orbea, MD, assistant professor of medicine, Cleveland Clinic.
At SLEEP 2022, Cinthya Pena Orbea, MD, assistant professor of medicine, Cleveland Clinic, discussed how socioeconomic factors can influence sleep-disordered breathing.
What did your study find about the relationship between socioeconomic status and sleep-disordered breathing?
There are many socioeconomic factors that can influence sleep, and that could be neighborhood factors, access to care, education. In our study, what we wanted to study is the association between ADI—which stands for area deprivation index, which is a biomarker of neighborhood socioeconomic disadvantage—the association of these and sleep disorder breathing measures. What we found was that sleep-related hypoxia was higher among those people living in higher areas of deprivation.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
